BridgeMD
HIsTological and CLinical effects of Imipramine in the treatment of patients with cancer over-expressing Fascin1. (HITCLIF)
EU CTIS ID: 2023-504943-15-00
What this study is testing
To assess whether treatment with Tofranil© produces significant changes in the histological and molecular manifestations of the epithelial-mesenchymal transition (EMT) in the period from tumor diagnosis by biopsy to surgical resection. The evaluation of the Main Objective will be carried out in the histological examination of the tumor piece product of the surgical resection; usually at 2-6 weeks for group A and between 3-6 months for neoadjuvant patients (group B).
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Resectable tumor.
- Obtaining Written Informed Consent.
- Diagnosis of colon, rectal or triple negative breast cancer by biopsy.
- Overexpression of fascina1 in primary tumor.
- Patient over 18 years of age
You likely can't join if
- Metastatic disease at diagnosis or not candidates for neoadjuvant therapy.
- Woman of childbearing age who refuses to use any contraceptive method.
- Colorectal cancer with clinical symptoms of sub-obstruction or obstruction.
- Known diagnosis of major depressive disorder, bipolar depression, or psychosis.
- ECOG scale 3 or 4.
- Severe renal failure (GFR <30 mL/min).
See the full eligibility criteria
- Resectable tumor.
- Obtaining Written Informed Consent.
- Diagnosis of colon, rectal or triple negative breast cancer by biopsy.
- Overexpression of fascina1 in primary tumor.
- Patient over 18 years of age
- Metastatic disease at diagnosis or not candidates for neoadjuvant therapy.
- Woman of childbearing age who refuses to use any contraceptive method.
- Colorectal cancer with clinical symptoms of sub-obstruction or obstruction.
- Known diagnosis of major depressive disorder, bipolar depression, or psychosis.
- ECOG scale 3 or 4.
- Severe renal failure (GFR <30 mL/min).
- Hepatic failure or bilirubin > 2 mg/dl.
- Suspected inability to comply with treatment adequately or conditions that limit its reliability (psychiatric illness, drug addiction, etc.).
- History of heart disease.
- Patient on current treatment with SSRIs, SNRIs, MAOIs, tramadol or trazadone or within the 14 days prior to recruitment.
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.